Iniparib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	2	12	—	—	2007-10
Malignant Breast Neoplasm	Phase3	Phase 3	1	3	—	—	2007-10
Malignant Lung Neoplasm	Phase2	Phase 2	0	1	—	—	2010-05
Malignant Ovarian Neoplasm	Phase2	Phase 2	0	3	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRCA2 Mutation1
Iniparib	Malignant Pancreatic Neoplasm

Clinical trials

Trials with this intervention (13)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–13 of 13 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01593228	Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial	completed	Phase 3	37	SanofiINDUSTRY	4	Sep 19, 2017	clinicaltrials
NCT01204125	Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients(SOLTI NEOPARP)